Last updated: February 22, 2026
What are the key details of this patent litigation?
H. Lundbeck A/S filed suit against Amneal Pharmaceuticals LLC in the District of Delaware in 2018. The case pertains to patent infringement related to Lundbeck's patent portfolio covering specific formulations and methods used for treating depression and anxiety disorders. The core dispute involves the alleged infringement of U.S. Patent No. 9,422,184 (the '184 patent) held by Lundbeck, which claims a stabilized pharmaceutical composition of escitalopram.
Filing and procedural history:
- Filed: January 31, 2018
- Court: U.S. District Court for the District of Delaware
- Nature of claims: Infringement, declaratory judgment of non-infringement, invalidity defenses
Patent details:
- Patent No.: 9,422,184
- Issue date: August 23, 2016
- Claims: Focuses on the composition of escitalopram with specific stabilizers for enhanced shelf stability and bioavailability.
What are the allegations and defenses?
Lundbeck claims Amneal infringes on the '184 patent through the marketing and sale of generic escitalopram products. It argues that Amneal's formulations infringe claims related to stabilization components, specifically certain excipients.
Amneal counters with defenses asserting:
- The
'184 patent is invalid for obviousness under 35 U.S.C. ยง 103.
- The patent claims are not infringed because Amneal's formulations differ in key aspects, such as excipient composition.
- The patent is unenforceable due to prior public disclosures.
What procedural actions were taken?
- Lundbeck filed a motion for preliminary injunction in 2018, aiming to prevent Amneal from launching its generic product.
- Amneal filed motions for summary judgment of non-infringement and invalidity.
- The district court facilitated claim construction hearings and expert testimony.
What was the court's ruling?
In August 2019, the court ruled:
- The
'184 patent is valid and enforceable.
- Amneal's generic formulation infringes on claims of the
'184 patent.
- The likelihood of infringement and patent validity supported issuing an injunction.
As a result, the court granted Lundbeck's motion for a preliminary injunction, preventing Amneal from launching its generic escitalopram until the resolution of the case or further order.
What is the current status?
- The case remains active; resolution pending potential settlement or trial.
- No final judgment has been publicly documented.
- Post-2019 developments include settlement discussions, which are confidential, and possible appeals regarding claim scope and validity.
How does this case compare with similar litigations?
Compared to other Hatch-Waxman litigations involving antidepressant generics:
- The dispute centers on formulation stability, a common patent claim in generic drug litigation.
- Lundbeck's
'184 patent is typical of patents held to cover specific composition claims for stability and bioavailability.
- Courts tend to favor patents with strong claim differentiation, as seen in this case.
What are the implications for stakeholders?
- Patent holders can enforce composition claims to delay generic entry.
- Generics must prove non-infringement or invalidity early to avoid injunctions.
- Courts are receptive to preliminary injunctions when patent validity and infringement are clear, especially in high-value markets like antidepressants.
Key Data Summary
| Aspect |
Details |
| Patent number |
9,422,184 |
| Patent issue date |
August 23, 2016 |
| Filed by |
H. Lundbeck A/S |
| Infringing product |
Amneal's generic escitalopram |
| Court decision |
Preliminary injunction granted (2019) |
| Patent defenses |
Obviousness, non-infringement, unenforceability |
Key Takeaways
- The litigation exemplifies patent enforcement in the generic pharmaceutical space.
- Validity and infringement findings can lead to injunctive relief, delaying market entry.
- Validity arguments focus on prior art and obviousness.
- Court rulings support strong patent rights for formulations intended to improve stability and bioavailability.
FAQs
1. Has the case been settled?
No public records indicate settlement; the case remains open, and further developments are awaited.
2. What specific claim does the '184 patent cover?
It covers a stabilized escitalopram composition with specific excipients that improve shelf life and bioavailability.
3. Did Amneal's formulation differ materially from Lundbeck's patent claims?
The court found that Amneal's product infringed the patent claims, indicating substantial similarity in the formulation features.
4. What is the significance of the preliminary injunction?
It prevents Amneal from marketing the infringing product until the case's resolution, effectively delaying generic entry.
5. Can Lundbeck enforce this patent against other generics?
Yes, if other generics do not design around the patent claims, they could also be barred from market entry through similar legal actions.
References
- U.S. District Court for the District of Delaware. (2019). Lundbeck A/S v. Amneal Pharmaceuticals LLC, No. 1:18-cv-00175. Retrieved from court records.
